Annals of Hepatology (Mar 2023)

P- 34 HEPATOCELLULAR CARCINOMA IN CHILE; A RETROSPECTIVE MULTICENTER STUDY OF 856 PATIENTS

  • Blanca Norero,
  • Gonzalo Latorre,
  • Diego Reyes,
  • Carlos Benitez,
  • Rodrigo Wolff,
  • Marco Arrese,
  • Macarena Viñuela Morales,
  • Matias Torres Parada,
  • Gabriel Mezzano,
  • Herman Aguirre,
  • Javiera Busquets,
  • Edmundo Martinez,
  • Maria Elisa Tapia,
  • Natalia Mendoza,
  • Claudia Pavez,
  • Alexandra Ginesta,
  • Fernando Gomez,
  • Jorge Contreras,
  • Edgar Sanhueza,
  • Monserrat Rius,
  • Andrea Jimenez,
  • Lorena Castro,
  • Javier Brahm,
  • Guillemo Silva,
  • Alvaro Urzua,
  • Jaime Poniachick,
  • Edith Contreras,
  • José Miguel Leiva,
  • Edmundo Aravena,
  • Macarena Larrain,
  • Nicolás Lama,
  • Olga Barajas,
  • Alejandro Ferrada,
  • Pauline Herman,
  • Pamela Yaquich,
  • Raúl Lazarte,
  • Rodrigo Zapata

Journal volume & issue
Vol. 28
p. 100936

Abstract

Read online

Introduction and Objectives: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Still, there are epidemiological and clinical data in Latin America. In Chile, this is the first study regarding HCC with a significant number of patients. This study aimed to obtain and analyze clinical and epidemiological data of Chilean patients with HCC. Materials and Methods: Multicenter study from 12 Chilean hospitals that have members of the Chilean Association of Hepatology as members of their staff. Clinical records from 2015-2021 were included. Kaplan-Meier survival curves and Cox regression analysis were obtained. Results: We obtained data from 856 patients with HCC from 12 different centers. Median age 67 years old; 58.7% male. Cirrhosis is present in 91.2% (779) of cases. Main risk factors reported: fatty liver 47.9%(410), alcohol 19.6% (68), viral 12.2%(104) and autoimmune 3.5% (30). The median MELD score was 11.7 (CI95% 11,4-12). 38% (322) were diagnosed during surveillance; this was associated with earlier BCLC stage (OR 2,6; CI95%1,9-3,4). BCLC stages at diagnosis were 0; 8,2%(69), A: 38,5%(326), B:29,9%(253), C: 15,4%(130) and D: 8,2%(69). The main initial treatments were TACE, ablation, resection, liver transplant and sorafenib in 27,4%(226), 19,3%(159), 11,4%(94), 8%(66) and 5,5%(45), respectively. 53,4%(452) pts were in Milan Criteria at diagnosis. 9,1%(78) patients got a liver transplant. Five-year survival was 24% (CI95%20-28). The main factors associated with survival are depicted in Figure 1. Conclusions: Fatty liver was remarkably the main risk factor reported for HCC in our Chilean cohort. This is a worrisome number since NAFLD is on the rise worldwide, and especially in Latin America. Surveillance is key for early detection. The liver function defined by Child-Pugh and HCC stage using BCLC staging is strongly associated with survival. Liver transplant is still a scarce treatment resource.